Phentermine/Topiramate ER — Membership Pricing

Other medications in Weight Management

• Setmelanotide
• Cellulose/Citric Acid Hydrogel
• Naltrexone/Bupropion ER

About Phentermine/Topiramate ER

Phentermine topiramate extended-release (ER) is approved for chronic weight management in adults who are overweight or obese and have at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol. It's not a magic bullet but rather an adjunct to a reduced-calorie diet and increased physical activity, helping patients achieve and maintain clinically significant weight loss.

This medication is a combination of two active ingredients: phentermine and topiramate. Phentermine is a sympathomimetic amine anorectic, meaning it works primarily by stimulating the central nervous system to suppress appetite. It helps you feel fuller and less hungry. Topiramate, on the other hand, is an anticonvulsant medication that has been shown to contribute to weight loss through several mechanisms, including increasing feelings of satiety, making foods taste less appealing, and potentially increasing energy expenditure. The extended-release formulation ensures a steady release of the medication throughout the day, providing sustained appetite control.

The cost of phentermine topiramate ER can vary significantly based on several factors, including the dosage, the pharmacy you use,

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Phentermine/Topiramate ER is approved for (FDA label)

Phentermine and topiramate extended-release capsules are indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition Limitations of Use The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

Source: Read the full FDA label on DailyMed. Label effective date: May 18, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Phentermine/Topiramate ER (FDA label)

Phentermine and topiramate extended-release capsules are available in four strengths (phentermine mg/topiramate mg): 3.75 mg/23 mg - purple cap imprinted with VIVUS and purple body imprinted with 3.75/23 7.5 mg/46 mg - purple cap imprinted with VIVUS and yellow body imprinted with 7.5/46 11.25 mg/69 mg - yellow cap imprinted with VIVUS and yellow body imprinted with 11.25/69 15 mg/92 mg - yellow cap imprinted with VIVUS and white body imprinted with 15/92 Extended-release capsules: (phentermine mg/topiramate mg) 3.75 mg/23 mg ( 3 ) 7.5 mg/46 mg ( 3 ) 11.25 mg/69 mg ( 3 ) 15 mg/92 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 876bd763-13fa-481e-b579-c2fc44dbf3c2. SPL document ID: 52217277-c719-2f2f-e063-6394a90a6699. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Phentermine/Topiramate ER (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Embryo-Fetal Toxicity [ see Warnings and Precautions (5.1) and Use in Specific Populations (8.1 , 8.6) ] Suicidal Behavior and Ideation [see Warnings and Precautions (5.2) ] Risk of Ophthalmologic Adverse Reactions [see Warnings and Precautions (5.3) ] Mood and Sleep Disorders [see Warnings and Precautions (5.4) ] Cognitive Impairment [see Warnings and Precautions (5.5) ] Slowing of Linear Growth [see Warnings and Precautions (5.6) ] Metabolic Acidosis [see Warnings and Precautions (5.7) ] Decrease in Renal Function [see Warnings and Precautions (5.8) ] Risk of Seizures with Abrupt Withdrawal of phentermine and topiramate extended-release capsules [see Warnings and Precautions (5.9) ] Kidney Stones [see Warnings and Precautions (5.10) ] Oligohydrosis and Hyperthermia [see Warnings and Precautions (5.11) ] Hypokalemia [see Warnings and Precautions (5.12) ] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions [ see Warnings and Precautions (5.13) ] Serious Skin Reactions [ see Warnings and Precautions (5.14) ] Anaphylaxis and Angioedema [ see Warnings and Precautions (5.15) ] Allergic Reactions Due to Inactive Ingredients FD&C Yellow No. 5 [see Warnings and Precautions (5.16) ] Most common adverse reactions in: Adults (incidence ≥ 5% and at least 1.5 times placebo) are: paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 876bd763-13fa-481e-b579-c2fc44dbf3c2. SPL document ID: 52217277-c719-2f2f-e063-6394a90a6699. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Phentermine/Topiramate ER (FDA label)

Phentermine and topiramate extended-release capsules are contraindicated in patients: Who are pregnant [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release capsules, or idiosyncrasy to the sympathomimetic amines. Anaphylaxis and angioedema have occurred with topiramate [ see Warnings and Precautions (5.15) ]. Pregnancy ( 4 ) Glaucoma ( 4 ) Hyperthyroidism ( 4 ) Taking or within 14 days of stopping monoamine oxidase inhibitors ( 4 ) Known hypersensitivity to any component of phentermine and topiramate extended-release capsules or idiosyncrasy to sympathomimetic amines ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 876bd763-13fa-481e-b579-c2fc44dbf3c2. SPL document ID: 52217277-c719-2f2f-e063-6394a90a6699. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Phentermine/Topiramate ER (FDA label)

Embryo-Fetal Toxicity : Can cause fetal harm. In patients who can become pregnant, a negative pregnancy test is recommended before initiating phentermine and topiramate extended-release capsules and monthly during therapy; advise use of effective contraception. Phentermine and topiramate extended-release capsules are available through a limited program under a Risk Evaluation and Mitigation Strategy (REMS) ( 5.1 ). Suicidal Behavior and Ideation : Monitor for depression or suicidal thoughts. Discontinue phentermine and topiramate extended-release capsules if symptoms develop ( 5.2 ). Risk of Ophthalmologic Adverse Reactions : Acute myopia and secondary angle closure glaucoma have been reported. Immediately discontinue phentermine and topiramate extended-release capsules if symptoms develop. Consider phentermine and topiramate extended-release capsules discontinuation if visual field defects occur ( 5.3 ). Mood and Sleep Disorders : Consider dosage reduction or discontinuation for clinically significant or persistent mood or sleep disorder symptoms ( 5.4 ).

Source: FDA prescribing information (DailyMed). Set ID: 876bd763-13fa-481e-b579-c2fc44dbf3c2. SPL document ID: 52217277-c719-2f2f-e063-6394a90a6699. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Phentermine/Topiramate ER (FDA label)

Table 5 displays clinically significant drug interactions with phentermine and topiramate extended-release capsules. Table 5. Clinically Significant Drug Interactions with Phentermine and Topiramate Extended-Release Capsules Monoamine Oxidase Inhibitors Clinical Impact Concomitant use of phentermine with monoamine oxidase inhibitors (MAOIs) increases the risk of hypertensive crisis.

Source: FDA prescribing information (DailyMed). Set ID: 876bd763-13fa-481e-b579-c2fc44dbf3c2. SPL document ID: 52217277-c719-2f2f-e063-6394a90a6699. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.